Clinical Observation Of DPP-4 Inhibitors In The Treatment Of T2DM

[Objective] This paper mainly clinical observation on metformin, glimepiride insulin combined with placebo and combined with the use of DPP-4 inhibitors(saxagliptin) the curative effect in treating type 2 diabetes mellitus. [Methods] Collected 60 cases of patients with type 2 diabetes, divided into experimental group and control group, each group consisted of 10 cases. The experimental group was metformin(500mg/times, 2 times a day)+ saxagliptin(5mg/day,before breakfast), glimepiride(2mg/day)+saxagliptin, insulin(total 50IU-80 IU/day)+saxagliptin, respectively, group A, group B, group C. In control group, metformin, glimepiride and insulin combined with placebo respectively for the D group, E group, F group. After 4 weeks, 12 weeks observe the value of blood glucose, Hb A1 c, BMI, HOMA-IR, HOMA-β,which in the observation group and the control group. [Results] After treatment, The Hb A1 c, BMI, HOMA-IR, FPG, 2h PG in the observ-ant iongroup of metformin were significantly decreased, and the HOMA-β index values were significantly higher than the control group(P<0.05). The FPG, 2h PG and Hb A1 c in the observation group of glimepiride were significantly decreased, and the HOMA-β values were significantly increased in the control group(P<0.0 5). FPG, 2h PG and Hb A1 c in the observation group were significantly lower than those of the control group of insulin, and the HOMA-β values were signifycan- tly higher than those of the control group(P<0.05). [Conclusions] Saxagliptin combined with metformin, glimepiride, insulin in type 2 diabetic patients compare with metformin, glimepiride, insulin combined with placebo, can more effectively control blood sugar, reduce glycated hemoglobin, does not increase the weight, improve insulin resistance and β cell function. But the long-term efficacy, combined with the safety, tolerability, small side effect, low incidence of hypoglycemia in many other features have yet to be further studied.